Precise and robust fit-for-purpose biomarker immunoassay methods are needed to support preclinical biotherapeutic development, with single biomarker assay development. Creative Biolabs provides robust assay performance with high precision, a wide dynamic range, and straightforward custom assay development, supporting biomarker analysis for research use. We now provide custom osteosarcoma-9 (OS9) analysis services for global clients.
OS9 is an ER-resident lectin that targets misfolded glycoproteins to the ER-associated degradation (ERAD) pathway through recognition of specific N-glycans by its mannose-6-phosphate receptor homology (MRH) domain. OS9 is necessary for recognition of terminally misfolded non-glycosylated proteins or improperly folded glycoproteins, binding with them for their retention in ER, and transferring them to ubiquitination machinery for degradation.
Previous studies revealed that the CaSR and OS-9 co-localize in the ER in COS-1 cells by confocal microscopy. OS9 is highly expressed in tumor tissue. There are three isoforms of this protein: OS9.1, OS9.2 and OS9.3. OS9.1 is the longest isoform containing 667 aa. OS9.2 lacks aa 535-589, whereas OS9.3 lacks aa 456-470 and 535-589. Both isoform 1 and isoform 2 are N-glycosylated, ubiquitously expressed in human tissues and are amplified in tumors.
Creative Biolabs has developed antibodies which can recognize different isoforms of OS9. The antibodies could be used in various immunochemical techniques such as ELISA, immunoblotting and immunoprecipitation. Creative Biolabs offers a wide range of options to measure OS9 level in appropriate samples including:
Biomarker analysis provides prognostic, predictive, and pharmacodynamic (PD) information for therapeutic interventions. If you need OS9 analysis services, please feel free to contact us for more information.
Browse Analytes Based on Alphabetical Listing:
For Research Use Only.